Supreme Court to Hear Arguments on “Skinny Labeling” Case Impacting Generic Drug Access

The U.S. Supreme Court scheduled oral arguments for Wednesday on a case concerning “skinny labeling,” a practice used by generic drug makers.

Skinny labeling involves seeking approval to market a generic for only certain indications of a brand‑name drug, avoiding patented uses and potential infringement lawsuits.

The issue dates back to the Hatch‑Waxman Act, which created pathways for generics to enter the market, and the court’s decision could affect how readily generics become available.

Industry observers will watch the outcome closely because it may shape future strategies for generic entry and impact patient access to lower‑cost medicines.